← 治験一覧に戻る
KHK 4827の第3相臨床試験
基本情報
- NCT ID
- NCT02052609
- ステータス
- 完了
- 試験のフェーズ
- 第3相
- 試験タイプ
- 介入
- 目標被験者数
- 155
- 治験依頼者名
- Kyowa Kirin Co., Ltd.
概要
This study is designed to evaluate the safety and efficacy of long-term exposure to KHK4827 in subjects with plaque psoriasis (psoriasis vulgaris, psoriatic erythroderma) who have completed Study 4827-003 (Study 003)and in subjects with pustular psoriasis (generalized) or psoriatic erythroderma who have completed the Study 4827-004 (Study 004).
対象疾患
Psoriasis VulgarisPsoriatic ArthritisPustular; Psoriasis, Palmaris Et PlantarisPsoriatic Erythroderma
介入
KHK4827 140mg SC(DRUG)
KHK4827 210mg SC(DRUG)
依頼者（Sponsor）
協和キリン株式会社(INDUSTRY)